Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.
Kürzel S, Blaudszun AR, Stahl L, Herbst R, Kroschinsky F, Birkmann J, Hänel A, Schaefer-Eckart K, Ehninger G, Fiedler F, Bornhäuser M, Fricke S, Hänel M. Kürzel S, et al. Among authors: blaudszun ar. J Cancer Res Clin Oncol. 2022 May;148(5):1171-1181. doi: 10.1007/s00432-021-03702-7. Epub 2021 Jun 26. J Cancer Res Clin Oncol. 2022. PMID: 34176014 Clinical Trial.
Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications.
Blache U, Weiss R, Boldt A, Kapinsky M, Blaudszun AR, Quaiser A, Pohl A, Miloud T, Burgaud M, Vucinic V, Platzbecker U, Sack U, Fricke S, Koehl U. Blache U, et al. Among authors: blaudszun ar. Front Immunol. 2021 May 3;12:658314. doi: 10.3389/fimmu.2021.658314. eCollection 2021. Front Immunol. 2021. PMID: 34012442 Free PMC article.
Correction: Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow‑up of 14.4 years.
Kürzel S, Blaudszun AR, Stahl L, Herbst R, Kroschinsky F, Birkmann J, Hänel A, Schaefer-Eckart K, Ehninger G, Fiedler F, Bornhäuser M, Fricke S, Hänel M. Kürzel S, et al. Among authors: blaudszun ar. J Cancer Res Clin Oncol. 2023 Feb;149(2):929-931. doi: 10.1007/s00432-022-04324-3. J Cancer Res Clin Oncol. 2023. PMID: 36083312 No abstract available.